Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.

Julian PanesGeert R D'HaensBruce E SandsWilliam K K WuNervin LawendyNicole KulisekXiang GuoJoseph WuIvana VranicRemo PanaccioneSeverine Vermeire

Published in: United European gastroenterology journal (2024)

GOV: NCT00787202; NCT01465763; NCT01458951; NCT01458574; NCT01470612; NCT03281304.

Keyphrases